Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315134 | 1.00 | CHRNA7 (0.33) | CHRNA7CYP4A11CYP4F2WNT3ARXFP1 | |
| SCHEMBL314638 | 0.91 | CHRNA7 (0.32) | CHRNA7CYP4A11CYP4F2RXFP1 | |
| SCHEMBL314637 | 0.91 | CHRNA7 (0.32) | CHRNA7CYP4A11CYP4F2RXFP1 | |
| SCHEMBL316422 | 0.90 | CYP3A4 (0.38) | GRM5FYNCYP11B1CYP11B2 | |
| SCHEMBL316423 | 0.90 | CYP3A4 (0.38) | GRM5FYNCYP11B1CYP11B2 | |
| SCHEMBL5275422 | 0.90 | RXFP1 (0.44) | CHRNA7RXFP1 | |
| SCHEMBL2142885 | 0.90 | CHRNA7 (0.44) | CHRNA7CYP4A11CYP4F2RXFP1 | |
| SCHEMBL5283290 | 0.90 | CHRNA7 (0.44) | CHRNA7CYP4A11CYP4F2RXFP1 | |
| SCHEMBL2138931 | 0.90 | RXFP1 (0.44) | CHRNA7RXFP1 | |
| SCHEMBL5278877 | 0.88 | KDM1A (0.36) | CHRNA7RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | CHRNA7 4780/4885CYP4A11 285/4885CYP4F2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.